Beauty Health (NASDAQ:SKIN) Announces Earnings Results

Beauty Health (NASDAQ:SKIN) issued its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.02, Zacks reports. Beauty Health had a negative return on equity of 44.83% and a negative net margin of 8.11%. Beauty Health updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Beauty Health Trading Up 4.4 %

Shares of SKIN traded up $0.06 during trading hours on Wednesday, reaching $1.42. The stock had a trading volume of 649,947 shares, compared to its average volume of 1,325,838. The company has a market cap of $176.25 million, a P/E ratio of -3.38 and a beta of 0.84. Beauty Health has a 52 week low of $0.91 and a 52 week high of $5.17. The company has a quick ratio of 5.57, a current ratio of 6.56 and a debt-to-equity ratio of 9.23. The firm has a 50-day moving average of $1.59 and a 200 day moving average of $1.57.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group upped their target price on shares of Beauty Health from $1.25 to $1.75 and gave the company a “hold” rating in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $2.55.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.